Liquid Biopsy Diagnostics: Our Research is Supported by the State of North Rhine-Westphalia. "Fragmentomics by LIQOMICS"
In May, we kicked off our latest research project, “Fragmentomics by LIQOMICS”, supported with approx. €370,000 in funding from the state of North Rhine-Westphalia.
With this project, we aim to push the boundaries of liquid biopsy diagnostics. By analyzing fragmentation patterns of circulating tumor DNA (ctDNA) and applying AI-driven models, we’re working to significantly improve the sensitivity of minimal residual disease (MRD) detection — especially in lymphomas. The technology also holds great potential for application in other cancer types.
See the press release on the official website of ZukunftBIO.NRW.
